Moderna (MRNA) Change in Receivables (2018 - 2026)

Moderna (MRNA) has 9 years of Change in Receivables data on file, last reported at -$114.0 million in Q1 2026.

• Change in Receivables for Q1 2026 came in at -$114.0 million, up 59.29% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.0 million (up 116.95% YoY), and the FY2025 annual result was -$156.0 million, up 70.79% from the prior year.
• Change in Receivables improved to -$114.0 million in Q1 2026 per MRNA's latest filing, from -$859.0 million in the prior quarter.
• Over five years, Change in Receivables peaked at $1.6 billion in Q3 2023 and troughed at -$1.3 billion in Q4 2022.
• A 5-year average of -$181.6 million and a median of -$272.0 million in 2023 frame the typical range for Change in Receivables.
• On a YoY basis, Change in Receivables climbed as much as 40750.0% in 2023 and fell as far as 27100.0% in 2023.
• A 5-year view of Change in Receivables shows it stood at -$1.3 billion in 2022, then rose by 25.65% to -$974.0 million in 2023, then slipped by 23.82% to -$1.2 billion in 2024, then gained by 28.77% to -$859.0 million in 2025, then jumped by 86.73% to -$114.0 million in 2026.
• Business Quant data shows MRNA's Change in Receivables at -$114.0 million in Q1 2026, -$859.0 million in Q4 2025, and $1.0 billion in Q3 2025.